Full-Time

QA Engineer

Updated on 3/14/2025

Veeva Systems

Veeva Systems

5,001-10,000 employees

Quality and regulatory software solutions provider

Compensation Overview

$65k - $115kAnnually

+ Variable Bonus + Stock Bonus

Mid, Senior

Company Historically Provides H1B Sponsorship

Toronto, ON, Canada

Category
QA & Testing
Automation Testing
Quality Assurance
Required Skills
Agile
Requirements
  • 3+ years of relevant work experience, including software development and/or software test automation
  • Strong verbal and written communication skills
  • Understanding of Software QA methodologies, tools, and approaches (black box and/or automated testing) in a software company with short-release cycles
  • Experience in writing test cases and automating them, covering both sanity and in-depth testing including and not limited to boundary, negative, compatibility, and concurrency tests
  • Bachelor's/Master’s degree in Computer Science, Software Engineering, or equivalent experience
Responsibilities
  • Ability to work in an agile, small team environment with a focus on speed and quality
  • Create testing-related documentation, including test plans, test cases/scripts, and bug reports assessing quality and associated risk
  • Work closely with the automation group to automate features for better regression coverage
  • Develop deep expertise in the product
  • Conduct QA tests and verify outcomes within schedules/timelines
  • Work with software engineers, product managers, and other QA testers in an Agile team environment
  • Participate in product and feature design reviews with Software Engineers and Product Managers
Desired Qualifications
  • Experience with Jira, Confluence, and TestRail
  • Experience in a SaaS environment that has an agile development process

Veeva Systems offers software solutions for quality, regulatory, and advertising claims management, focusing on consumer products and chemical companies. Their cloud-based platform provides visibility and traceability throughout the product journey, ensuring compliance with regulations and accelerating time-to-market. Veeva differentiates itself by addressing the specific challenges of these industries, building on its experience in the Life Sciences sector. The company operates on a subscription model, serving over 950 customers globally.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

2007

Simplify Jobs

Simplify's Take

What believers are saying

  • Veeva's expansion into chemical and consumer goods markets meets growing compliance demands.
  • Partnerships like Boehringer Ingelheim enhance Veeva's reputation in clinical trial innovation.
  • Veeva's CRM Pulse boosts global healthcare engagement metrics and communication.

What critics are saying

  • Increased competition from emerging cloud-based providers may erode Veeva's market share.
  • Rapid technological advancements require continuous innovation, straining Veeva's resources.
  • Data privacy concerns and regulatory scrutiny could impact Veeva's operations and trust.

What makes Veeva Systems unique

  • Veeva Systems leads in cloud-based software for the global life sciences industry.
  • Veeva's Development Cloud enhances trial efficiency and accelerates drug development.
  • Veeva's subscription model ensures steady revenue and continuous software updates.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Parental leave

PTO

Free food

Health, dental, & vision insurance

Gym membership reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Simply Wall St
Mar 13th, 2025
Veeva Systems (NYSE:VEEV) Announces Tina Hunt's Retirement From Board Before 2025 Shareholders Meeting

Veeva Systems (NYSE:VEEV) announces Tina Hunt's retirement from board before 2025 shareholders meeting.

PR Newswire
Mar 11th, 2025
Boehringer Ingelheim Partners With Veeva To Launch 'One Medicine Platform'

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseasesINGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine collaboration in March 2022. The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases."Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world," said Oliver Fink, head of learning, process and digitalization at Boehringer Ingelheim. "Veeva Development Cloud provides the technology foundation for Boehringer's One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.""By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals," said Rik van Mol, senior vice president, Veeva Development Cloud. "This is an exciting milestone toward realizing Veeva and Boehringer's shared mission to advance the use of data and technology to modernize clinical trials and deliver better patient outcomes."Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloudAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health

Data Centre Magazine
Mar 11th, 2025
Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform'

INGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ - Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud.

PharmiWeb
Mar 11th, 2025
Boehringer Ingelheim Partners With Veeva To Launch ‘One Medicine Platform’

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseasesLondon, UK — 11 March 2025 — ​​​Today, ​Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud​.​​ They ​first announced the One Medicine collaboration in March 2022.​ ​The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development.With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimise trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.“Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world,” said Oliver Fink, head of learning, process and digitalisation at Boehringer Ingelheim. “Veeva Development Cloud provides the technology foundation for Boehringer’s One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.”“By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals,” said Rik van Mol, senior vice president, Veeva Development Cloud. “This is an exciting milestone toward realising Veeva and Boehringer’s shared mission to advance the use of data and technology to modernise clinical trials and deliver better patient outcomes.”Veeva Development Cloud is the technology foundation for product development​,​ bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloudAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain

Investing.com
Mar 6th, 2025
Citi maintains Veeva stock Buy rating, $307 target post Q4 beat

Additionally, Veeva Systems secured its fourth top 20 customer in the Safety category and witnessed a top 20 customer commit comprehensively to its clinical solutions.